IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v10y2019i1d10.1038_s41467-019-12361-9.html
   My bibliography  Save this article

Metabolomic adaptations and correlates of survival to immune checkpoint blockade

Author

Listed:
  • Haoxin Li

    (Dana-Farber Cancer Institute
    Broad Institute of MIT and Harvard
    Harvard University)

  • Kevin Bullock

    (Broad Institute of MIT and Harvard)

  • Carino Gurjao

    (Dana-Farber Cancer Institute
    Broad Institute of MIT and Harvard)

  • David Braun

    (Dana-Farber Cancer Institute)

  • Sachet A. Shukla

    (Dana-Farber Cancer Institute)

  • Dominick Bossé

    (Dana-Farber Cancer Institute)

  • Aly-Khan A. Lalani

    (Dana-Farber Cancer Institute)

  • Shuba Gopal

    (Broad Institute of MIT and Harvard)

  • Chelsea Jin

    (Bristol-Myers Squibb)

  • Christine Horak

    (Bristol-Myers Squibb)

  • Megan Wind-Rotolo

    (Bristol-Myers Squibb)

  • Sabina Signoretti

    (Dana-Farber Cancer Institute)

  • David F. McDermott

    (Beth Israel Deaconess Medical Center)

  • Gordon J. Freeman

    (Dana-Farber Cancer Institute)

  • Eliezer M. Allen

    (Dana-Farber Cancer Institute
    Broad Institute of MIT and Harvard
    Brigham and Women’s Hospital, Harvard Medical School)

  • Stuart L. Schreiber

    (Broad Institute of MIT and Harvard
    Harvard University)

  • F. Stephen Hodi

    (Dana-Farber Cancer Institute
    Brigham and Women’s Hospital, Harvard Medical School)

  • William R. Sellers

    (Dana-Farber Cancer Institute
    Broad Institute of MIT and Harvard)

  • Levi A. Garraway

    (Dana-Farber Cancer Institute
    Broad Institute of MIT and Harvard
    Brigham and Women’s Hospital, Harvard Medical School)

  • Clary B. Clish

    (Broad Institute of MIT and Harvard)

  • Toni K. Choueiri

    (Dana-Farber Cancer Institute
    Brigham and Women’s Hospital, Harvard Medical School)

  • Marios Giannakis

    (Dana-Farber Cancer Institute
    Broad Institute of MIT and Harvard
    Brigham and Women’s Hospital, Harvard Medical School)

Abstract

Despite remarkable success of immune checkpoint inhibitors, the majority of cancer patients have yet to receive durable benefits. Here, in order to investigate the metabolic alterations in response to immune checkpoint blockade, we comprehensively profile serum metabolites in advanced melanoma and renal cell carcinoma patients treated with nivolumab, an antibody against programmed cell death protein 1 (PD1). We identify serum kynurenine/tryptophan ratio increases as an adaptive resistance mechanism associated with worse overall survival. This advocates for patient stratification and metabolic monitoring in immunotherapy clinical trials including those combining PD1 blockade with indoleamine 2,3-dioxygenase/tryptophan 2,3-dioxygenase (IDO/TDO) inhibitors.

Suggested Citation

  • Haoxin Li & Kevin Bullock & Carino Gurjao & David Braun & Sachet A. Shukla & Dominick Bossé & Aly-Khan A. Lalani & Shuba Gopal & Chelsea Jin & Christine Horak & Megan Wind-Rotolo & Sabina Signoretti &, 2019. "Metabolomic adaptations and correlates of survival to immune checkpoint blockade," Nature Communications, Nature, vol. 10(1), pages 1-6, December.
    • Handle: RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-12361-9
    DOI: 10.1038/s41467-019-12361-9
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-019-12361-9
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-019-12361-9?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Lei Zhang & Li Jiang & Liang Yu & Qin Li & Xiangjun Tian & Jingquan He & Ling Zeng & Yuqin Yang & Chaoran Wang & Yuhan Wei & Xiaoyue Jiang & Jing Li & Xiaolu Ge & Qisheng Gu & Jikun Li & Di Wu & Antho, 2022. "Inhibition of UBA6 by inosine augments tumour immunogenicity and responses," Nature Communications, Nature, vol. 13(1), pages 1-16, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-12361-9. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.